Clara Maluquer
Overview
Explore the profile of Clara Maluquer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzalez-Gil C, Morgades M, Lopes T, Fuster-Tormo F, Montesinos P, Barba P, et al.
Haematologica
. 2024 Aug;
110(1):206-211.
PMID: 39113657
No abstract available.
2.
Ribera J, Morgades M, Ribera J, Montesinos P, Cano-Ferri I, Martinez P, et al.
Hemasphere
. 2024 Apr;
8(4):e67.
PMID: 38566805
No abstract available.
3.
Heald J, Lopez A, Pato M, Ruiz-Xiville N, Cabezon M, Zamora L, et al.
Blood Adv
. 2024 Mar;
8(11):2691-2694.
PMID: 38536941
No abstract available.
4.
Castano-Diez S, Pomares H, Esteban D, Guijarro F, Jimenez-Vicente C, Zugasti I, et al.
Br J Haematol
. 2023 Nov;
204(3):892-897.
PMID: 38013238
Recently modified diagnostic criteria for chronic myelomonocytic leukaemia (CMML) have lowered the cut-off for absolute monocytosis. In the largest series to date, we have analysed 313 CMML patients, including 104...
5.
Cortellini A, Tabernero J, Mukherjee U, Salazar R, Sureda A, Maluquer C, et al.
Lancet Oncol
. 2023 Mar;
24(4):335-346.
PMID: 36898391
Background: COVID-19 sequelae can affect about 15% of patients with cancer who survive the acute phase of SARS-CoV-2 infection and can substantially impair their survival and continuity of oncological care....
6.
Maluquer C, Bellosillo B, Mussetti A, Domingo-Domenech E, Parody R, Fernandez-Ibarrondo L, et al.
EJHaem
. 2022 Jul;
2(1):109-111.
PMID: 35846093
Objectives: Chimeric antigen receptor T cells (CARTs) against CD19 antigen represent an effective therapy for relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL). There is no diagnostic test able to predict which...
7.
Pinato D, Ferrante D, Aguilar-Company J, Bower M, Salazar R, Mirallas O, et al.
Eur J Cancer
. 2022 Jun;
171:64-74.
PMID: 35704976
Background: Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. Methods: Capitalizing on...
8.
Pinato D, Aguilar-Company J, Ferrante D, Hanbury G, Bower M, Salazar R, et al.
Lancet Oncol
. 2022 Jun;
23(7):865-875.
PMID: 35660139
Background: The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination...
9.
Cortellini A, Salazar R, Gennari A, Aguilar-Company J, Bower M, Bertuzzi A, et al.
Eur J Cancer
. 2022 May;
170:10-16.
PMID: 35576848
Introduction: A significant proportion of patients with cancer who recover from Coronavirus Disease 2019 (COVID-19) may experience COVID-19 sequelae in the early post-infection phase, which negatively affect their continuity of...
10.
Cortellini A, Gennari A, Pommeret F, Patel G, Newsom-Davis T, Bertuzzi A, et al.
J Natl Cancer Inst
. 2022 Apr;
114(7):979-987.
PMID: 35417006
Background: Fifteen percent of patients with cancer experience symptomatic sequelae, which impair post-COVID-19 outcomes. In this study, we investigated whether a proinflammatory status is associated with the development of COVID-19...